Gelonghui, November 21丨CStone Pharmaceuticals-B (02616.HK) announced that the company has reached a commercial global strategy partnership with Pharmalink Store-L.L.C - O.P.C (“Pharmalink”). Pharmalink is a well-known pharmaceutical company headquartered in the United Arab Emirates. According to the licensing and commercialization agreement, Pharmalink will obtain the commercialization rights for Suguliximab in the Middle East and North Africa regions, including Saudi Arabia, the United Arab Emirates, Kuwait, Qatar, Oman, Bahrain, Algeria, Tunisia, Egypt, Morocco, Libya, and South Africa.
基石药业-B(02616.HK)与Pharmalink就舒格利单抗在中东和非洲地区达成战略合作
Vertex Pharmaceuticals B (02616.HK) has reached a global strategy partnership with Pharmalink for the development of Suglituzumab in the Middle East and Africa.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated